Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6062-6069

  Hu, Shuiying ^a   Chen, Zhaoyuan ^a   Franke, Ryan ^a   Orwick, Shelley ^a   Zhao, Ming ^b   Rudek, Michelle A ^b   Sparreboom, Alex ^a   Baker, Sharyn D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; SORAFENIB; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG INHIBITION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; MAMMAL CELL; MOUSE; NONHUMAN; OOCYTE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE; XENOPUS LAEVIS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZENESULFONATES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CARRIER PROTEINS; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROLYSIS; INDOLES; MICE; MICE, KNOCKOUT; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SWINE; XENOPUS LAEVIS;

EID: 70349669267     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0048     Document Type: Article

References (50)

1. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23: 329-336
2. WilhelmS, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844 (Pubitemid 44480537)
3. Chow LQ, Eckhardt SG. Sunitinib: fromrational design to clinical efficacy. J Clin Oncol 2007;25: 884-896
4. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100:184-198
5. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008;49:2246-2255 (Pubitemid 351323149)
6. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577-2582 (Pubitemid 40490054)
7. Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21: 1267-1275 (Pubitemid 46831816)
8. Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2942 (Pubitemid 39434984)
9. Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-7914
10. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881-3888
11. Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004;64:2333-2337
12. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-3148
13. Li J, Cusatis G, Brahmer J, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007;6:432-438 (Pubitemid 47328313)
14. Nakamura Y, Oka M, Soda H, et al. Gefitinib ("Iressa," ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65: 1541-1546 (Pubitemid 40270183)
15. Shi Z, Peng XX, KimI W, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007;67:11012-11020 (Pubitemid 350145931)
16. Yang CH, Huang CJ, Yang CS, et al. Gefitinib reverses chemotherapy resistance in gefitinibinsensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 2005;65:6943-6949
17. Hu S, Niu H, Minkin P, et al. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 2008;7:1110-1120
18. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y. Inhibition of oat3-mediated renal uptake as a mechanism for drugdrug interaction between fexofenadine and probenecid. Drug Metab Dispos 2006;34: 743-747
19. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodiumion -dependent carnitine transporter. Nat Genet 1999;21:91-94 (Pubitemid 29036290)
20. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, SparreboomA. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 2008;84:704-709
21. Baker S, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 2009;85:208-211
22. Baker SD, Verweij J, Cusatis G, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85:155-163
23. -/- (triple-knockout) and wildtype mice. Mol Cancer Ther 2008;7:2280-2287
24. Wierdl M, Wall A, Morton CL, et al. Carboxylesterase- mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol Pharmacol 2003;64: 279-288 (Pubitemid 36909991)
25. Ambudkar SV. Drug-stimulatable ATPase activity in crude membranes of human MDR1- transfected mammalian cells. Methods Enzymol 1998;292:504-514
26. Hakime A, Hines-Peralta A, Peddi H, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology 2007;244:464-470 (Pubitemid 47080878)
27. Minkin P, Zhao M, Chen Z, Ouwerkerk J, GelderblomH, Baker SD. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;874:84-88
28. Zhao M, Rudek MA, He P, et al. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/ tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 2007;846:1-7. (Pubitemid 46149480)
29. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104: 3739-3745 (Pubitemid 39564452)
30. White DL, Saunders VA, Dang P, et al. OCT-1- mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704. (Pubitemid 44061372)
31. Okabe M, Szakacs G, Reimers MA, et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008;7:3081-3091
32. Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-4301 (Pubitemid 38802436)
33. Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66:8847-8857 (Pubitemid 44449203)
34. Grube M, Meyer zu Schwabedissen HE, Prager D, et al. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 2006;113:1114-1122
35. Lenihan DJ. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol 2008;26:5154-5155
36. Mann DL. Targeted cancer therapeutics: the heartbreak of success. Nat Med 2006;12:881-882
37. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-137 (Pubitemid 39485685)
38. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009;37:359-365
39. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61: 535-548
40. Vlaming ML, Mohrmann K, Wagenaar E, et al. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 2006; 318:319-327 (Pubitemid 43920772)
41. Zimmermann C, van deWetering K, van de Steeg E, Wagenaar E, Vens C, Schinkel AH. Speciesdependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos 2008;36:631-640
42. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting fromex tensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62: 6158-6164 (Pubitemid 35244466)
43. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117:3583-3592 (Pubitemid 350097013)
44. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolisma nd excretion of imatinib. Invest New Drugs 2009;27:31-40.
45. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-1012
46. Leis JF, Stepan DE, Curtin PT, et al. Central nervous systemfail ure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004;45:695-698 (Pubitemid 38256028)
47. Petzer AL, Gunsilius E, Hayes M, et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002;117: 623-625 (Pubitemid 34546037)
48. Takayam a N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous systeminvolvem ent of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002; 119:106-108
49. Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 2007;18:1282-1283 (Pubitemid 47244377)
50. Valcamonico F, Ferrari V, Amoroso V, et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009;91:47-50.